14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of DRMA
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Stronger technical forecast for Dermata Therapeutics, Inc. stock price after Monday trading.
(Updated on May 06, 2024)

Hold candidate since May 06, 2024 PDF

The Dermata Therapeutics, Inc. stock price gained 1.37% on the last trading day (Monday, 6th May 2024), rising from $0.336 to $0.341. During the last trading day the stock fluctuated 5.62% from a day low at $0.336 to a day high of $0.355. The price has been going up and down for this period, and there has been a -3.07% loss for the last 2 weeks. Volume fell on the last day by -7 thousand shares and in total, 14 thousand shares were bought and sold for approximately $4.74 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -26.29% during the next 3 months and, with a 90% probability hold a price between $0.173 and $0.280 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

DRMA Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, April 16, 2024, and so far it has risen 27.80%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Dermata Therapeutics, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $0.371. On a fall, the stock will find some support from the short-term average at $0.337. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Dermata Therapeutics, Inc. stock

Dermata Therapeutics, Inc. finds support from accumulated volume at $0.338 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.0189 between high and low, or 5.62%. For the last week the stock has had daily average volatility of 5.68%.

Our recommended stop-loss: $0.330 (-3.14%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from a pivot bottom found 14 days ago.)

Trading Expectations (DRMA) For The Upcoming Trading Day Of Tuesday 7th

For the upcoming trading day on Tuesday, 7th we expect Dermata Therapeutics, Inc. to open at $0.344, and during the day (based on 14 day Average True Range), to move between $0.310 and $0.371, which gives a possible trading interval of +/-$0.0303 (+/-8.90%) up or down from last closing price. If Dermata Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 17.80% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.338 (0.70%) than the resistance at $0.382 (12.27%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Earnings coming up

Dermata Therapeutics, Inc. will release earnings BMO on Thursday, May 09, 2024.The consensus among the analysts for the expected earnings (EPS) is -$0.360. We will update the financials statements for Dermata Therapeutics, Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 17.43% in the first trading day after earnings release.

Is Dermata Therapeutics, Inc. stock A Buy?

Dermata Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: -0.801 Hold/Accumulate Upgraded

Predicted Opening Price for Dermata Therapeutics, Inc. of Tuesday, May 7, 2024

Fair opening price May 7, 2024 Current price
$0.344 ( 0.97%) $0.341

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for DRMA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.363 6.52 %
R2 0.356 4.40 %
R1 0.351 3.09 %
Current price: 0.341
Support S1 0.337 -1.15 %
S2 0.332 -2.46 %
S3 0.325 -4.58 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.415 21.90 %
R2 0.400 17.44 %
R1 0.382 12.27 %
Current price 0.341
Support S1 0.338 -0.705%
S2 0.300 -11.86%
S3 0.267 -21.76%

FAQ

What is the symbol for Dermata Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Dermata Therapeutics, Inc. is DRMA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Dermata Therapeutics, Inc. Stock?
Dermata Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

How to buy Dermata Therapeutics, Inc. Stock?
Dermata Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Dermata Therapeutics, Inc. Stock.

What's the current price of Dermata Therapeutics, Inc. Stock?
As of the end of day on the May 06, 2024, the price of an Dermata Therapeutics, Inc. (DRMA) share was $0.341.

What is the 52-week high and low for Dermata Therapeutics, Inc. Stock?
The 52-week high for Dermata Therapeutics, Inc. Stock is $32.94 and the 52-week low is $11.07.

What is the market capitalization of Dermata Therapeutics, Inc. Stock?
As of the May 06, 2024, the market capitalization of Dermata Therapeutics, Inc. is 2.269M.

When is the next earnings date for Dermata Therapeutics, Inc.?
The upcoming earnings date for Dermata Therapeutics, Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About Dermata Therapeutics, Inc.

Dermata Therapeutics. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas... DRMA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT